Suproclone

Suproclone
Clinical data
ATC code	none;
Identifiers
	IUPAC name [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-propanoylpiperazine-1-carboxylate;
CAS Number	76535-71-2 ;
PubChem CID	53696;
ChemSpider	48481 ;
UNII	J4AM5D708G;
KEGG	D05975 ;
ChEMBL	ChEMBL2105531;
ECHA InfoCard	100.071.330
Chemical and physical data
Formula	C22H22ClN5O4S2
Molar mass	520.02 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N5CCN(C(=O)OC4C=1SCCSC=1C(=O)N4c2nc3nc(Cl)ccc3cc2)CC5)CC;
	InChI InChI=1S/C22H22ClN5O4S2/c1-2-16(29)26-7-9-27(10-8-26)22(31)32-21-18-17(33-11-12-34-18)20(30)28(21)15-6-4-13-3-5-14(23)24-19(13)25-15/h3-6,21H,2,7-12H2,1H3 ; Key:IBAUKGNDWVSETP-UHFFFAOYSA-N ;
	(what is this?) (verify)

Suproclone is a sedative and anxiolytic drug in the cyclopyrrolone family of drugs, developed by the French pharmaceutical company Rhône-Poulenc. Other cyclopyrrolone drugs include zopiclone, pagoclone and suriclone.

Suproclone is very similar in structure to the related drug suriclone, but little information has been published about it specifically. However it can be expected that the mechanism of action by which suproclone produces its sedative and anxiolytic effects is by modulating benzodiazepine receptors (resulting in an increased response to endogenous GABA), in a similar manner to other drugs of this class.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.